依据CT总碘摄取量预测胃癌新辅助化疗的反应

doi:10.16139/j.1007-9610.2019.01.008

摘要/Abstract

摘要： 目的: 前瞻性评估双能量CT（dual-energy computed tomography, DECT）中的总碘摄取（total iodine uptake, TIU）在预测胃癌病人新辅助化疗疗效和无进展生存期（progression-free survival, PFS）的应用价值。方法: 收集我院44例化疗前、后均行DECT扫描的局部进展期胃癌病人。计算肿瘤面积（%ΔS）,直径（%ΔD）和密度（%ΔHU）的变化率来评估WHO、RESCIST和Choi标准。同时计算肿瘤体积（%ΔV）和门静脉期TIU的变化率（%ΔTIU-p）来评估ROC曲线下的界值。统计学分析不同标准与组织病理退缩分级（Becker）或PFS间的关系。结果: 分别根据ΔV（43.34%,P=0.002）和ΔTIU-p（63.87%,P=0.002）的界值将病人分为反应组和非反应组。%ΔTIU-p标准与Becker间显示较强的相关性（r=0.602,P<0.001）,%ΔV显示中等相关（r=0.416, P=0.005）,而WHO（r=0.075, P=0.627）, RECIST（r=0.270, P=0.077）和Choi标准（r=0.238, P=0.120）与Becker间无相关性。%ΔTIU-p（P=0.001）和Choi标准（P=0.013）的反应组和非反应组PFS间差异具有统计学意义。结论: TIU-p可预测进展期胃癌病人新辅助化疗后病理退缩。%ΔTIU-p分析新辅助化疗后的PFS有一定意义。

关键词: 胃癌, 新辅助化疗, 总碘摄取量, 病理退缩, 无进展生存期

Abstract: Objective To evaluate prospectively the total iodine uptake (TIU) from dual-energy computed tomography (DECT) in predicting treatment efficacy and progression-free survival (PFS) time in the patients with gastric cancers after neoadjuvant chemotherapy (NAC). Methods Forty-four patients with locally advanced gastric cancer were given DECT before and after NAC. Changes in percentage of tumor area (%ΔS), diameter (%ΔD), and density (%ΔHU) were calculated to evaluate the WHO, RESCIST, and Choi criteria. Changes in percentage of tumor volume (%ΔV) and TIU in portal phase (%ΔTIU-p) were also calculated to determine cut-off points by ROC curves. Correlations between criteria and histomorphologic tumor regression grade (Becker) and between criteria and PFS were analyzed. Results Patients were divided into responders group and non-responders group by ΔV (43.34%, P=0.002) and by ΔTIU-p (63.87%, P=0.002), respectively. Higher correlation was present between criteria %ΔTIU-p and Becker grade (r=0.602, P<0.001) and moderate correlation between criteria %ΔV and Becker grade (r=0.416, P=0.005), while no correlation between Becker grade and WHO criteria (r=0.075, P=0.627), RECIST criteria (r=0.270, P=0.077) and Choi criteria (r=0.238, P=0.120). There were statistical diffe-rences significantly in PFS time of the patients between responder group and non-responder group when using criteria %ΔTIU-p (P=0.001) or Choi criteria (P=0.013). Conclusions TIU-p could be used to predict pathological regression in patients with advanced gastric cancer after NAC. Criteria %ΔTIU-p would become the parameter to study PFS time after NAC.

Key words: Gastric cancer, Neoadjuvant chemotherapy, Total iodine uptake, Pathologic regression, Progression-free survival

中图分类号:

R735.2

张阳, 张欢, 丁蓓, 袁菲, 马乾辰, 王柏松, 严福华, 杜联军. 依据CT总碘摄取量预测胃癌新辅助化疗的反应[J]. 外科理论与实践, 2019, 24(01): 33-39.

ZHANG Yang, ZHANG Huan, DING Bei, YUAN Fei, MA Qianchen, WANG Baisong, YAN Fuhua, DU Lianjun. Total iodine uptake in CT for predicting results of neoadjuvant chemotherapy in gastric cancer[J]. Journal of Surgery Concepts & Practice, 2019, 24(01): 33-39.

参考文献

[1] Cunningham D, Allum WH, Stenning SP, et al.Periope-rative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
[2] Ychou M, Boige V, Pignon JP, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phaseⅢ trial[J]. J Clin Oncol,2011,29(13):1715-1721.
[3] Bichev D, Treese C, Winterfeld MV, et al.High impact of histopathological remission for prognosis after perio-perative chemotherapy with ECF and ECF-Like regimens for gastric and gastroesophageal adenocarcinoma[J]. Oncology,2015,89(2):95-102.
[4] Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment[J]. Cancer,1981,47(1):207-214.
[5] Watanabe H, Okada M, Kaji Y, et al.New response evaluation criteria in solid TUMORs: revised RECIST guideline (version 1.1)[J]. Gan To Kagaku Ryoho,2009, 36(13):2495-2501.
[6] Ott K, Fink U, Becker K, et al.Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial[J]. J Clin Oncol,2003,21(24):4604-4610.
[7] Choi H. Response evaluation of gastrointestinal stromal tumors[J]. Oncologist,2008,13 Suppl 2:4-7.
[8] Yang D, Woodard G, Zhou C, et al.Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics[J]. Thorac Cancer,2016,7(5):535-542.
[9] Liu K, Li G, Fan C, et al.Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemothe-rapy[J]. Acta Radiol,2012,53(2):127-134.
[10] Stiller W, Skornitzke S, Fritz F, et al.Correlation of quantitative dual-energy computed tomography iodine maps and abdominal computed tomography perfusion measurements: are single-acquisition dual-energy computed tomography iodine maps more than a reduced-dose surrogate of conventional computed[J]. Invest Radiol,2015,50(10):703-708.
[11] Apfaltrer P, Meyer M, Meier C, et al.Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response?[J]. Invest Radiol,2012,47(1):65-70.
[12] Uhrig M, Sedlmair M, Schlemmer HP, et al.Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases[J]. Cancer Imaging,2013,13(3):306-313.
[13] Dai X, Schlemmer HP, Schmidt B, et al.Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Eur J Radiol,2013,82(2):327-334.
[14] Grady L.Random walks for image segmentation[J]. IEEE Trans Pattern Anal Mach Intell,2006,28(11):1768-1783.
[15] Becker K, Mueller JD, Schulmacher C, et al.Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer,2003, 98(7):1521-1530.
[16] Landis JR, Koch GG.The measurement of observer agreement for categorical data[J]. Biometrics,1977,33(1):159-174.
[17] Kiyabu M, Leichman L, Chandrasoma P.Effects of preo-perative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases[J]. Cancer,2015,70(9):2239-2245.
[18] Thian Y, Gutzeit A, Koh DM, et al.Revised Choi ima-ging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib[J]. Radiology,2014,273(2):452-461.
[19] Lee SM, Kim SH, Lee JM, et al.Usefulness of CT vo-lumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer[J]. Abdom Imaging,2009,34(4):430-440.
[20] Benjamin RS, Choi H, Macapinlac HA, et al.We should desist using RECIST, at least in GIST[J]. J Clin Oncol,2007,25(13):1760-1764.
[21] Motzer RJ, Michaelson MD, Redman BG, et al.Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2006,24(1):16-24.
[22] Tang L, Li ZY, Li ZW, et al.Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression[J]. Clin Radiol,2015,70(11):1198-1204.
[23] Park JO, Lee SI, Song SY, et al.Measuring response in solid tumors: comparison of RECIST and WHO response criteria[J]. Jpn J Clin Oncol,2003,33(10):533-537.
[24] Ahn SH, Garewal HS, Dragovich T.Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria[J]. J BUON,2008, 13(3):359-362.
[25] Dai X, Schlemmer HP, Schmidt B, et al.Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Eur J Radiol,2013,82(2):327-334.
[26] Thian Y, Gutzeit A, Koh DM, et al.Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib[J]. Radiology,2014,273(2):452-461.
[27] Krajewski KM, Guo M, van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma[J]. Eur Urol,2011,59(5):856-862.